Jensyn Cone Sullivan

Jensyn Cone Sullivan

Auto-generated profile, based on publicly available information

Jensyn Cone Sullivan

Department of Pathology University of Michigan Ann Arbor Michigan USA

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
30 May 2020 in Transfusion
Verified
Journal Article
Closed access
PDF file
WLWilliam J. Lane
William J. Lane
NGNicholas S. Gleadall
Nicholas S. Gleadall
JAJudith Aeschlimann
Judith Aeschlimann
SVSunitha Vege
Sunitha Vege
ASAlba Sanchis‐Juan
Alba Sanchis‐Juan
CWConnie M. Westhoff
Connie M. Westhoff

2 July 2022 in Transfusion
Verified
Journal Article
Closed access
MCMischa L. Covington
Mischa L. Covington
JCJensyn K. Cone‐Sullivan
Jensyn K. Cone‐Sullivan
CAChester Andrzejewski
Chester Andrzejewski
WLWen Lu
Wen Lu
RTReggie R. Thomasson
Reggie R. Thomasson
SSSean R. Stowell
Sean R. Stowell

10 August 2022 in Transfusion
Verified
Journal Article
Closed access
MPMaria Teresa Eyzaguirre Pellon
Maria Teresa Eyzaguirre Pellon
AWAnn Marie Walsh
Ann Marie Walsh
JWJennifer Willis
Jennifer Willis
JFJudith Forbes
Judith Forbes
JSJensyn Cone Sullivan
Jensyn Cone Sullivan

12 April 2026 in Transfusion
Verified
Journal Article
Closed access
PDF file
MCMischa L. Covington
Mischa L. Covington
EAElizabeth S. Allen
Elizabeth S. Allen
SCStella T. Chou
Stella T. Chou
SCStephanie Conrad
Stephanie Conrad
MEMariama Evans
Mariama Evans
WLWen Lu
Wen Lu

14 September 2023 in Journal of Clinical Apheresis
Verified
Journal Article
Closed access
JSJensyn Cone Sullivan
Jensyn Cone Sullivan
SCSteven E. Conklin
Steven E. Conklin
SCStephanie Conrad
Stephanie Conrad
CHCoby Horowitz
Coby Horowitz
MDMark Diethelm
Mark Diethelm
RCRaymond Comenzo
Raymond Comenzo

26 February 2026 in Transfusion Medicine Reviews
Verified
Journal Article
Open access
JSJensyn Cone Sullivan
Jensyn Cone Sullivan
JRJay S. Raval
Jay S. Raval
NZNicole D. Zantek
Nicole D. Zantek
DADavid L. Allison
David L. Allison
GGGaurav Gupta
Gaurav Gupta
KAKyle Annen
Kyle Annen
Primary thrombocytosis is associated with increased risk of thromboembolism and bleeding. Therapeutic plateletpheresis (TPP), capable of rapid, transient platelet (Plt) count reduction, is employed as an emergency intervention for symptomatic thrombocytosis while awaiting the therapeutic effect of medical cytoreductive therapy. Nonetheless, the effect of TPP on outcomes and optimal role for TPP remain poorly understood. Critical analytic review of highest-pertinence and -quality articles was performed with the goal of establishing current knowledge gaps to direct original case data collection. Retrospective review of TPP procedures at six United States sites over ten years was performed. Pre-TPP symptoms, medical cytoreduction, adverse events (AEs), and 30-day post-TPP outcomes were analyzed. Critical analytic review revealed no randomized controlled trial (RCT) or controlled trials (CT) of TPP versus first-line medical therapies, and insufficient information on symptoms, goals, criteria-based determination of course, and post-TPP outcomes. New data presented here details 45 adult patients receiving TPP for thrombocytosis. TPP was performed rarely (of n = 6 sites, median 4.5 TPP/10 years, range 4-20). The most frequent diagnosis was myeloproliferative neoplasm (MPN) (34, 75.6%). The most frequent symptoms were any neurologic symptoms (present pre-64.4% of TPPs). TPP goals were commonly Plt-related (n = 85, 94.4% total TPP) and were met in 72.9% of TPP with stated Plt-related goals. Often, (n = 11/50 single TPP or series) TPP was begun or continued despite resolution of the stated indication for TPP. AE occurred during 20% of TPP and were predominantly hypocalcemia related (17/18, 94.4%). Four patients died within 30 days post TPP, three of stroke, one of a non-stroke neurologic complication. All deaths were deemed unrelated to TPP. Critical analytic reviews revealed no RCTs or CTs, a paucity of data on TPP goals and prescribed courses, and significant variability in AE reporting. Little information on long-term outcomes is available. Without controlled evidence supporting clinical outcome benefit of TPP for symptomatic thrombocytosis, utilization is expected to be rare and guideline-informed, following careful consideration of known risk in the setting of unclear benefit.